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Isozymes of cyclic-3',S'-nucleotide phosphodiesterases in renal epithe-
hal LLC-PK1 cells. Metabolism of cAMP and cGMP by the major types
(families) of cyclic-3',5'-nucleotide phosphodiesterases (PDE) was
studied in confluent renal epithelial LLC-PKI cells grown in vitro.
LLC-PK1 cells mainly contain the cAMP-specific rolipram-sensitive
PDE type-IV (PDE-IV), the Ca2-calmodulin dependent PDE type-I
and cGMP-specific PDE type-V; all these PDEs are mainly localized in
cytosol. Analysis of PDE activities in soluble extract of LLC-PK1 cell
homogenate by FPLC ionex chromatography on Mono-Q column also
disclosed the presence of low activities of cGMP-stimulated PDE-II and
PDE-III. Moreover, activity of PDE-IV was resolved into four distinct
chromatographic peaks. The increase of cAMP level in response to
incubation of intact LLC-PK1 cells with vasopressin (AVP) was mark-
edly enhanced in the presence of rolipram, but not in the presence of
other PDE isozyme-specific inhibitors. Incubation with AVP and atrio-
peptin (ANP) together resulted in increase in cGMP and a small
decrease of cAMP accumulation in LLC-PK1 cells. Results of these
studies first show that the LLC-PK1 cells contain all five major types of
PDE isozymes where PDE-IV, PDE-I and PDE-V are quantitatively
predominant. The rolipram-sensitive PDE-IV, present in several chro-
matographically distinct forms, appears to be the key PDE isozyme
involved in control of cAMP generated in response to stimulation by
AVP in LLC-PK1 cells.
Multiple isozymes of cyclic-3' ,5 '-nucleotide phosphodiester-
ases (PDE)1 are increasingly recognized as critically important,
integral elements in intracellular signalling via cAMP and cGMP
PDE denotes cyclic-3',5'-nucleotide phosphodiesterase in general.
cAMP-PDE denotes PDE activity using cAMP as substrate, cGMP-
PDE denotes PDE activity using cGMP as substrate.
In this report, the PDE isozymes are classified as proposed by J.A.
Beavo [2, 3]. According to this nomenclature, PDE-I is the family of
PDE isozymes dependent on ionized calcium (Ca2) and calmodulin
(CaM); PDE-II is family of isozymes cAMP-PDE activity of which is
stimulated by low (M range) concentration of cGMP; the PDE-If I are
isozymes with low Kr., for cAMP and are sensitive to inhibition by
cilostamide, "cardiotonic inhibitors" and cGMP, but not inhibited by
rolipram; PDE-IV are isozymes with very high affinity and selectivity
for cAMP, are insensitive to compounds that inhibit PDE-III and are
selectively inhibited by rolipram; PDE-V are those isozymes which
specifically hydrolyze cGMP and activity of which is independent of
Ca2-CaM.
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[1—5]. The abundance, activities, intracellular localizations and
regulatory changes in response to various intrinsic modulators,
such as Ca2-calmodu1in (CaM) and cGMP, of PDE isozymes
all determine to a large degree the turnover rates [4—8] and thus
the steady state levels [61 of cyclic-3' ,5 '-nucleotides. Moreover,
PDE isozymes also quite likely contribute to intracellular
compartmentalization of cAMP and cGMP [1, 4, 8, 9], and also
may be a point of "cross-talk" between intracellular signalling
pathways via two or more second messengers within the same
cell [10].
Compared to a large body of data accumulated from studies
of nonrenal tissues and cell systems such as adipocytes [4],
myocardium [9], smooth muscle [11, 12], liver or neural tissue
[1—3], our present knowledge about the role of PDE isozymes in
renal epithelial cells and in other cell types populating the
nephron is only rudimentary. Isolation and characterization of
the major types of PDE isozymes from initial preparations using
whole homogenized kidney or major zones of renal tissue as
starting material [13—15] is of limited value, since these methods
cannot discern the role of individual PDEs in the regulation of
specific nephron segments and/or specific renal cell types.
initially, the studies of PDE activities in isolated glomeruli
and mixed cortical tubules have pointed out major differences in
the pattern of cyclic-3',5'-nucleotide hydrolysis within the
kidney [16]. These observations provided first evidence for the
presence of cGMP-stimulated PDE-II in glomeruli and of Ca2-
CaM-dependent PDE-I in cortical tubules [16]. Measurements
of cAMP and cGMP hydrolysis in specific segments of nephron
microdissected and permeabilized by freezing and hypotonic
shock [17, 18] provided initial information about distribution of
PDE activities along the specific sites of nephron [17—20].
However, such measurements on microsamples usually permit
neither determination of subcellular distribution of PDEs nor
detection of activities of those PDE isozymes which may be
present only in low abundance.
The LLC-PK1 renal epithelial cell line, which originated from
porcine kidney 121], frequently serves as a classic in vitro model
for studies of intracellular signalling in renal epithelia by
[8-Arg]-vasopressin (AVP) via cAMP [22—24] and also by atrio-
peptin (ANP) or endothelium-derived relaxing factor (EDRF)
via cGMP [24, 25].
With respect to PDE activities of LLC-PK1 cells, the only
information known to us to date is a report that most of
Rassier et a!: Metabolism of cAMP and cGMP in renal cells 89
concentrations): 20 m TES(N-tris[hydroxymethyl]methyl-2-
aminoethanesulfonic acid), 5 mt MgC12, 1 mt'i EDTA [ethyl-
enediaminetetraacetic acid], 1 mrvi EGTA [ethylene glycol tris
(J3-aminoethyl ether)-N,N,N' ,N'-tetraacetic acid], 5 mrvi /3-mer-
captoethanol, 0.1 M leupeptin, 0. 1 M pepstatin and 0.1 M
phenylmethyl sulfonate fluoride (PMSF), pH 7.5. When extract
was prepared for separation on ionex column, the homogeniza-
tion buffer also included 0.1% Triton X-100. For preparation of
cytosolic and membrane fractions from LLC-PK1 cells, the
homogenization buffer contained 0.3 M sucrose but no Triton
X-100. Homogenization and all subsequent steps were con-
ducted at 0 to 4°C (Fig. 1).
FPLC® ion exchange chromatography
Supernatant S2
"Extract"
Pellet discard
Fig. 1. Flow-diagram depicting procedure for preparation homoge-
nate-extract of LLC-PK, cells. The extract was then subjected to
Mono-Q FPLC chromatography.
cAMP-PDE activity is found in cytosol rather than in mem-
branes, and that histidine and imidazol can stimulate cAMP-
PDE activity [26]. In the present study we employed basic
biochemical separation techniques, PDE sensitivity to PDE
isozyme-selective synthetic inhibitors [2, 5, 27, 28], as well as
the responses to natural modulators such as Ca2-CaM and/or
cGMP, to determine which catabolic pathways for cAMP and
cGMP are present and functional in LLC-PK cells. Further-
more, we also studied some aspects of the PDE isozymes role
in AVP-dependent cAMP metabolism of intact LLC-PK1 cells.
Methods
Cell culture
LLC-PK1 cells were originally provided by Dr. Joseph S.
Handler, National Heart, Lung, and Blood Institute (Bethesda,
Maryland, USA). Cells were grown at 37°C in humidified 5%
CO2 in 95% air, using Dulbecco's Modified Eagle's Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), 100
U/ml penicillin, 100 g/ml streptomycin, and 2 mrvt glutamine.
Cells were subcultured weekly by trypsinization and were
plated at a density of 10,000 cells/cm2 into either 24-well culture
plates, petri dishes or culture flasks. When cell layers were
confluent and 20 to 24 hours before experiments, culture media
was changed to serum-free DMEM.
Preparation of the cell extract
The LLC-PK1 cell monolayers were rinsed twice with ice-
cold phosphate-buffered saline (PBS) and the cells were scraped
into "homogenizing buffer" of the following composition (final
The twice-rinsed cells were harvested and homogenized in a
buffer containing Triton X- 100 in a Potter-type Teflon-glass
homogenizer using 10 strokes. The homogenate was then sub-
jected to fractionation according to the flow diagram shown in
Figure 1. The final preparation denoted as "extract" was
subjected to HPLC chromatography on FPLC® Mono-Q col-
umn 5/5 (Pharmacia®) ion exchange column [14, 29]. The
LLC-Pk1 extracts containing 10 to 15 mg total protein, were
loaded on the Mono-Q-HR 5/5 column pre-equilibrated with
elution buffer of the following composition (final concentra-
tion): 20 m TES, 1 mivi EDTA, 0.5 mM EGTA, 5 mM
/3-mercaptoethanol, 0.01% Triton X-l00, 0.1 mit leupeptin, 0.1
mM PMSF, 0.1 mtvi pepstatin (pH 7.5) and 75 mr'i NaCI. In the
course of the isocratic phase elution (with a buffer containing 75
mM NaCI) the bulk of proteins, as detected by online monitor-
ing using 0D280 nm, were removed. The eluate in isocratic
phase had no PDE activity. The Mono-Q column [29] was then
eluted with linear NaCI gradient 75 to 500 m, which was raised
in final phase to 1.0 M NaCI. The eluate was collected in 0.4 ml
fractions into ice chilled tubes containing ethylene glycol [15].
Fractions were immediately mixed and placed on ice. The
ethylene glycol in the final concentration of 30% stabilized PDE
activity [15]. PDE activity was measured in individual and/or
pooled fractions either immediately or after short (several days)
storage at —20°C. Preliminary experiments showed no appre-
ciable loss of PDE enzymatic activity during storage for up to
one week in medium containing ethylene glycol.
Subcellular fractionation
Harvested LLC-PK1 cells were homogenized as described
above, except the homogenizing medium contained 0.3 M
sucrose and no Triton X-100. Homogenate was ultracentrifuged
at 100,000 x g for 60 minutes. Supernatant was decanted and
the pellet was rehomogenized and ultracentrilugated again.
First and second supernatants were pooled to constitute "cy-
tosolic fraction." The washed pellet was resuspended and taken
as total membrane fraction, referred to as "membrane frac-
tion."
Phosphodiesterase (PDE) assay
Activity of PDE was measured always by incubating the
enzyme fractions in a reaction mixture (final volume 100 d) of
the following composition (final concentrations): 10 mM
MgSO4, 2 mi'vi EGTA, 0.1% bovine serum albumin, 15 mM
$
Supernatant Si
Homogenate
Ultracentrifugation (100,000 x g/40 mm)
I
Pellet: rehomogenized in buffer
$
Ultracentrifugation (100,000 x g/40 mm)
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Tris-HC1 adjusted to pH 7.5, and either 0.5 tM [3H[-cAMP, or
0.5 zsi [H]-cGMP as substrate,
In experiments examining the activity of Ca2-ca1modulin
(CaM)-dependent PDE, the reaction mixture also contained
2.01 mivi CaCI2, to obtain 10 M Ca2 [16, 30, 311, and 10 g/m1
of calmodulin (CaM). The PDE activity in aliquot samples
incubated without Ca2 and CaM (but containing 2 mM EGTA,
vide supra) was subtracted as basal activity [31]. In experiments
examining the effect of PDE inhibitors, the stock solutions of all
inhibitors of PDE were made in 100% dimethylsulfoxide
(DMSO), and the incubation media contained 0.1% (DMSO).
Hydrolysis of cyclic-3' ,5 '-nucleotides was less than 20% of the
substrate and was linearly proportional to incubation time and
enzyme protein. Protein content was measured by the Brad-
ford's method [32].
Measurement of cAMP content in intact LLC-PK, cells
After serum-free media were aspirated off, cell layers were
first washed (twice) with warm (37°C) Kreb's ringer buffer
(KRB) of following composition (final concentrations): 140 mM
NaCI, 5 m KCI, 1.2 mi MgSO4, 2 mr,i CaCI2, 2 mri NaH2PO4,
10 mM Na-acetate, 10 mri D-glucose buffered to pH 7.4 with
20 mM HEPES. All PDE inhibitors were dissolved in DMSO
and final concentrations of DMSO were always 0.1%. As a
basic design, LLC-PKI cells were first incubated in 0.5 ml KRB
without (controls) or with PDE inhibitors for 30 minutes in a
shaking water bath (1 cycle/sec) at 37°C for 30 minutes to allow
complete penetration of inhibitors into the cells. At the end of
the 30 minute incubation, incubation media was aspirated off
and replaced with medium of the same composition including
appropriate PDE inhibitors, but also containing [8-Arg]-vaso-
pressin (AVP) and/or [1-28] human atriopeptin (ANP); basal
were controls without hormone. Incubation then continued for
the next two minutes (or as specified in Results). At the end of
the second incubation period, the medium was removed and 0.5
ml of 10% trichloroacetic acid (TCA) and [H]cAMP and/or
[3H]cGMP tracers for recoveries were added. The cell culture
plate was then placed in a shaking ice bath to quantitatively
extract cellular cAMP and/or cGMP. Supernatant was trans-
ferred into test tubes kept at a 4°C. The TCA was extracted by
water-saturated ether and cyclic-3' ,5'-nucleotides were deter-
mined in duplicate by radioimmunoassay (RIA) on preacety-
lated samples [33, 34]. As determined in control experiments,
none of the employed PDE inhibitors interfered with RIA for
cAMP or cGMP. The average cellular protein per well was
determined by a modified Lowry method [16, 351 in four wells
treated similarly (except for precipitation with 10% TCA) as
experimental wells. Each data point reported represents the
average from duplicate wells. To minimize variability from
experiment to experiment, effect of inhibitors and/or hormones
was always tested using paired design. LLC-PK1 cells were
seeded, grown on the same plate, were incubated without
(controls) or with test agents simultaneously, and also all
subsequent analysis were conducted in parallel [33, 341.
Detection of PDE-IV by Western blot
Extract homogenate or samples of pooled eluate peaks were
first precipitated with 15% TCA and 0.1% Na deoxycholate.
The precipitates were solubilized in a small volume (20 to 40 p.1)
of "sample buffer": 8% sodium dodescyl sulfate (SDS), 5%
mercaptoethanol, 2 mivi EDTA, 20 mrvi Tris-HC1, pH 8.0, while
heated at 100°C for five minutes. Electrophoresis was per-
formed on pre-cast polyacrylamide gradient mini gels (4 to 20%)
(Scheicher & Schuell, Kenne, USA) in the presence of 0.1%
SDS at pH 8.2 (30 to 35 mAmp used per gel). After electropho-
resis the gel was transferred to a gel-blotting assembly. Poly-
peptides separated on the gel were electrophoretically blotted
onto nitrocellulose or polyvinylidene difluoride (PVDF) sheets
(Millipore Co., Bedford, Massachusetts, USA) at 200 mAmp.
The pattern of polypeptide on the sheet was visualized using
Gold-Blot system (Integrated Separation System, Massachu-
setts, USA). For identification of PDE-related polypeptide, the
PVDF sheet was rinsed with PBS and incubated with a "block-
ing" solution (5% powdered milk, 0.05% Tween 20 in PBS-
buffer) for one hour. The PVDF sheet was then incubated with
a primary polyclonal rabbit antibody (batch K- 111; dilution
1:100). Antibody K-l 11 was raised in rabbits (in the laboratory
of Dr. Marco Conti, Department of Pediatrics, University of
North Carolina Medical School, Chapel Hill, North Carolina,
USA) by immunization with 22-amino acid synthetic polypep-
tide, the sequence of which was deduced from regions of
PDE-IV sequences of eDNA (close to N-terminal) for isozyme
ratPDE3 (PDE-IVD) where it started on base 465, and cDNA
for isozyme ratPDE4 (PDE-IV) started at base 334 [36, 37].
The incubation continued for two hours with gentle shaking at
room temperature. The sheet was then rinsed with PBS,
(washed 3 times, each 5 mm) with a washing solution (0.05%
Tween 20 and 0.05% ND-40 dissolved in PBS buffer) and again
with PBS buffer. The sheet was then incubated with 1251-protein
A in a PBS buffer containing 5% milk powder (50 to 75 p.1
protein A per ml PBS buffer) for 1.5 hours. The sheet was then
rinsed extensively with PBS buffer, washing solution and PBS
buffer in sequence. The final blot was air-dried and exposed to
an x-ray film (type X-OMAT, AR, Eastman Kodak, Rochester,
New York, USA).
Materials and solutions
Rolipram, 4-(3-cyclopentyloxy-4-methylphenyl)-2-pyrolidone
(ZK 62711) was a gift of Berlex Laboratories (Cedar Knolls,
New Jersey, USA). Cilostamide, N-cyclohexyl-N-methyl-
4(1 ,2-dihydro-2-oxo-6-quinohyloxy)butyramide(OPC-3639) was
a gift of Otsuka Pharmaceutical Company (Osaka, Japan).
Vinpocetine (TCV-3B) 14-ethoxycarbonyl-(3a, 16a-ethyl)-l4, 15-
eburnamenine, was a gift from Takeda Chemical Industries,
Ltd. (Osaka, Japan); Zaprinast (M&B 22,948) [2-0-
Propoxyphenyl-8-azapurin-6-one] was a gift from May and
Baker, Ltd. (Essex, England, UK); Milrinone, 1 ,6-Dihydro-2-
methyl-6-oxo-[3 ,4'-bipyridine]-5-arbonitrile(WIN-47203) was a
gift from Sterling-Winthrop Research Institute (Rensselaer,
New York, USA). The QAE-Sephadex A-25 resin and FPLC
system was from Pharmacia, LKB, Inc. (Piscataway, New
Jersey). Trifluoperazine (TFP), N-(6-aminohexyl)-5-chloro-l-
napthalene sulfonamide HCI (W-7), and bovine brain calmodu-
lin were purchased from Sigma Chemical Co. (St. Louis,
Missouri, USA). The cAMP-RIA kit were from BlO MED
TECH (BT-300); [8-3HJcGMP, ammonium salt, 10 to 30 Ci!
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mmol was from Amersham Co., TRK-392. cGMP-RIA kits
(NEX-133), '251-protein-A, NEN (NEX-1466) 2 to 10 jCi/g
and [2,8-3H]-cAMP, ammonium salt, NEN (NEX 275) 30 to 50
Ci/mmol were all purchased from New England Nuclear (Bos-
ton, Massachusetts, USA). All other reagents and chemicals,
all of the highest purity grade, were purchased from standard
suppliers. [3HJ-cAMP and [3H]-cGMP were, prior to use as
substrates or as RIA recovery tissues, purified using methods of
Kincaid and Manganiello [38].
Results were evaluated statistically using Student's t-test for
paired or for group comparisons, as specified in the Results.
Results
PDE activities
The homogenate-extract from LLC-PK1 cells, prepared as
shown on Figure 1, was first assayed for cAMP-PDE and
cGMP-PDE activities using either 0.5 pM [3H]-cAMP or 0.5 /JM
[3H]-cGMP as substrates. In this preparation, the cAMP-PDE
activity (58 13 pmol cAMP/mg protein/mm; mean SEM, N
= 4)was significantly (P < 0.05) lower than cGMP-PDE activity
(105 14 pmol cGMP/mg protein/mm; mean SEM, N = 4).
Moreover, cGMP-PDE was stimulated by Ca2-CaM to a
higher degree (A + 290 63%) than cAMP-PDE (A + 101
18%). Thus, LLC-PK1 cells have much higher overall capacity
to catabolize cGMP than cAMP (Table 1).
PDE distributions
To determine which PDE isozyme activities are present in
cytosol and which are membrane-associated, LLC-PK1 cells
were gently homogenized in an isotonic (0.3 M sucrose) me-
dium, containing inhibitors of proteases but without detergent
(detailed in Methods), and the homogenate was separated by
ultracentrifugation into cytosol and total membrane fraction.
Specific PDE activities are shown in Figure 2 and total PDE
activities in Table 1.
Specific activity of cAMP-PDE and even more so of the
cGMP-PDE was much higher in cytosol than in membranes
(Fig. 2). In cytosol, cGMP-PDE activity was about three times
higher than cAMP-PDE, whereas specific activities of both
cAMP-PDE and cGMP-PDE in membrane fraction were within
a similar range. About 50% of the cytosolic and 30% of the
membrane-bound cAMP-PDE was of PDE-IV, as indicated by
sensitivity to inhibition by 3 M rolipram (Fig. 2). Addition of 3
tM milrinone, 3 tM cilostamide or 5 /LM cGMP had no
significant effect on cAMP-PDE either in cytosol or in mem-
brane fraction.
The Ca2-CaM-dependent cAMP-PDE activity, PDE type-I,
was also higher in cytosol than in membrane fraction and was
very sensitive to the specific PDE-I inhibitor [2, 27], vinpocet-
me (Fig. 2). Most of the PDE activity hydrolyzing preferentially
cGMP was dependent on Ca2-CaM and sensitive to vinpocet-
me (Fig. 2, Table 1). Results of total PDE isozyme activities
(Table 1) indicate that the total cAMP-PDE activity in LLC-
PK1 cells consist mainly of Ca2-CaM-dependent PDE type-I,
hydrolyzing cAMP and then rolipram-sensitive PDE type-IV
which is for cAMP; the bulk of PDE-I and PDE-IV were present
in cytosol.
Table 1. Total activities of PDE enzymes hydrolyzing cAMP (cAMP-
PDE) and cGMP (cGMP-PDE) in cytosolic and membrane fractions
of LLC-PK1 cells
Cytosol Membranes
pmollmin
cAMP-PDE
Basal cAMP-PDE (without Ca2) 322 31 78 11
PDE-IV (rolipram-sensitive PDE) 148 10 34 5
PDE-I (Ca2-CaM-sensitive cAMP-PDE) 287 33 26 11
cGMP-PDE
Basal cGMP-PDE (without Ca2) 904 51 140 29
PDE-I (Ca2-CaM-sensitive cGMP-PDE) 1344 364 209 64
Basal cAMP-PDE was assayed without Ca2 but with 2 mi EGTA in
the medium; PDE-IV was measured as basal cAMP-PDE inhibitable by
3 /M rolipram; PDE-I was determined as cAMP-PDE assayed with
Ca2 and CaM minus the basal cAMP-PDE. Basal cGMP-PDE was
assayed without Ca2 but with 2 ms EGTA in the medium; PDE-I was
determined as cGMP-PDE assayed with Ca2 and CaM minus the basal
cGMP-PDE.
Data are presented as mean SEM, N = 3.
The Ca2-CaM-independent activities of cGMP-PDE both in
cytosolic and membrane fraction were inhibited to a large
degree by zaprinast (Fig. 2), an inhibitor relatively specific for
PDE-V [2, 5, 28]. Of all PDE activities, specific or total,
Ca2-CaM-stimulated cGMP-PDE is the highest PDE activity,
both soluble and membrane-bound.
lonex chromatography
The extract from homogenized LLC-PK1 cells, prepared in
hypotonic buffer containing Triton X-100 (Fig. 1) to optimize
solubilization of PDEs [31], was subjected to FPLC chromatog-
raphy on MONO-Q 5/5 column using elution with linear NaCI
gradient (Fig. 3). The eluate resolved into five distinct peaks
(peak #1 to #5) of PDE activity (Fig. 3). There was no
detectable PDE activity in the isocratic (75 mrvi NaCl) phase of
eluate, during which the bulk of protein was removed, and all
the PDE activities were eluted by the NaCl gradient at concen-
trations > 220 mivi NaCl.
In the first PDE peak (peak #1), eluted at 231 5 mrvi Nacl,
the PDE in the absence of Ca2-CaM hydrolyzed only cGMP,
not cAMP. However, the large portion of the cGMP-PDE was
Ca2-CaM dependent (Figs. 3 and 4). The activity at the right
"downhill" part (higher NaC1) of peak #1, was greatly stimu-
lated (more than 20-fold) by the addition of Ca2-CaM. The
PDE in peak #1 also hydrolyzed cAMP, but only in the
presence of Ca2-CaM, and with about 10 times lower effi-
ciency than cGMP (data not shown).
In contrast to peak #1, all the PDE activities eluted in the
higher NaCl gradient range (NaCl> 300 mM) hydrolyzed cAMP
exclusively and were completely insensitive to effects of added
Ca2-CaM. The Ca2-CaM-insensitive cAMP-PDEs were con-
sistently resolved into four peaks: peak #2 (at 325 5 mM
NaCl); peak #3 (at 386 8 mM); peak #4 (at 455 15 mM) and
peak #5 (at 548 19 mM).
The PDE activities separated in the five major peaks of eluate
were characterized further by the sensitivity to cAMP-PDE
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Fig. 2. Subcellular distribution of specific
activities of PDE isozymes in cytosol and
membrane fractions of LLC-PKJ cells.
Cytosolic and membrane fractions were
prepared as detailed in Methods. Each bar
represents mean SEM of four experiments
(N 4). Activities of eAMP-PDE and of
GMP PDE cGMP-PDE were assayed with 0.5 /LM cAMPC - or0.5 tIM cGMP, respectively, as substrates.
Basal activity denotes the activity in the
absence of Ca2 without modulators or
inhibitors added. ZAP = with 5 bLM Zaprinast;
vinpocetine = with 50 gM vinpocetine; PP
with 3 /.LM rolipram; Ca2 + CaM = with 10
jIM Ca2 and 10 jcg/ml of calmodulin.
*denotes activity significantly (t-test, P <
0.05) different from basal. All percent
Basal ZAP Ca2 + Ca2 + CaM + differences were statisticatly significant (P <
CaM vinpocetine 0.05, 1-test).
2
= Fig. 3. The profile of PDE activities in extract
from LLC-PK3 cells as eluted from FPLC
Mono-Q column by NaCI gradient. Figure
portrays a representative experiment, N = 5.
Ordinate (right side), specific activity of PDE
pmoles of cyclic-3' ,5'-nucleotide (cAMP or
cGMP)/mg protein/mm; ordinate (left side),
NaCI concentration in fractions of eluate.
Abscissa: fraction number. Fractions of eluate
prior to fraction #75 were without PDE
activity and are not shown. Numbers in
circles denote peaks of PDE activities #l—#5.
Symbols are: (—•—S—) cAMP-PDE; (AssA.);
cGMP-PDE; (—Li——Li—) Ca2 f-CaM-dependent
cGMP-PDE.
isozyme-specific synthetic inhibitors [2, 5, 28, 361, since, as
seen in Figures 3 and 4, the Ca2-CaM-dependent and -inde-
pendent eGMP-PDE activities were not symmetrically distrib-
uted in the elution profile of peak #1. The fractions of the eluate
under peak #1 were pooled from several regions or "zones" of
peak #1 (denoted lA, lB, 1C) and compared with a fraction of
peak #1 with the highest Ca2t -CaM-dependent cGMP-PDE
activity (usually fraction 84 or 85) which was denoted as
"zone" 1D (Fig. 4). In these preparations, the cGMP-PDE
activity was assayed in the presence of Ca2 -CaM and tested
for the response to isozyme-specifie PDE inhibitors: vinpocet-
inc and trifluoroparazine (TFP) for Ca2-CaM dependent PDE-I
and zaprinast for Ca2 -CaM-independent, cGMP-speeific
PDE-V (Fig. 4). The PDE activity in zone IA was strongly
inhibited by Zaprinast (by —76%), and to a much lesser degree
by vinpocetine (—10%) and by TFP (—26%). In zone lB and in
zone 1C, the inhibition by zaprinast was gradually lesser, and
inhibition by vinpocetine was higher than in IA (Fig. 4).
However, the most distinct contrast in effects of the three
inhibitors provides comparison between zones lA, lB and lC,
which were mostly Ca2-CaM independent, that is, PDE-V,
and zone 1D (Fig. 4). In contrast to zone 1A, zone lD showed
B Membranes
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j5,:fln
Basal RI' Ca2+ Cat2+CaM±
CaM vinpocetine
0)
0
a
0)
E
C
B
0
E
a.
c
E
C)
F
C
B
a.
7000
2000
1000
0.75
0.50
0.25
0
100
Fraction
A Cytos&
• 86 3%)
cAMP-PDE cGMP-PDE
C0
0
a0
E
C
E
0
Ea
600 (+141 t34%)
400
0
-J
200
61
2%)la
CaM vinpocetine
0
CaM ZAP Ca Ca2+CaM
CaM vinpocetine
Rassier et a!: Metabolis,n of cAMP and cGMP in renal cells 93
only modest inhibitory effect by zaprinast (—25%), whereas
vinpocetine (—63%), or TFP (—76%) strongly inhibited cGMP-
PDE (Fig. 4).
Fractions collected and pooled under peaks #2, #3, #4 and
#5 were evaluated for the sensitivity to inhibitors of low Km
cAMP-PDEs [2, 4, 5, 28, 361, namely rolipram (specific for
PDE-IV), and cilostamide or milrinone (specific for PDE-III).
The cAMP-PDE activity in peaks #2 to #5 was extensively
inhibited (—65% to —85%) by 3 M rolipram (Fig. 5). Both
milrinone (3 ) and cilostamide (3 M) showed lesser, but
consistent inhibitory effect in all the four (#2 to 5) peaks; the
inhibition by cilostamide was less pronounced than with milri-
none (Fig. 5). These results, taken together, suggest that the
majority of PDE activity in peaks #2, #3, #4 and #5 consist of
rolipram-sensitive PDE-IV, and to a much smaller extent PDE-
III.
Desalted and concentrated peaks #1 to 5 were analyzed by
Western blot (Fig. 6) using polyclonal antibodies raised against
a specific 22 amino acid oligopeptide sequence deduced from
cDNAs (Methods) for two rat rolipram-sensitive PDE-IV iso-
zymes [2, 35], which are coded by distinct genes: PDE-IVB,
ratPDE4, and PDE-IVD, ratPDE3 [classifications ref. #2 and
#28, respectively]. This analysis showed immunoreactive
bands (Fig. 6) in peaks #2, 3, 4 and 5, within the narrow
molecular wt range of 59 kd to 63 kd; the most prominently
stained band was in peak #5. Notably, the rolipram-sensitive
PDE-IV in peaks #4 and #5 also showed the highest increases
in specific PDE activity, 16x and 20x, respectively, compared
to the original homogenate-extract.
Finally, we searched all fractions of the Mono-Q eluate for
the presence of PDE-II, that is, the cGMP-stimulated cAMP-
PDE [2, 3]. All fractions were assayed with 0.5 M cAMP as a
substrate, without or with the addition of 5 p.M cGMP. Also the
reducing agent, 3.7 mri /3-mercaptoethanol, was added to the
incubation to optimize the assay conditions for PDE-II [14, 39].
When assayed under these conditions low, but consistently
detectable, cGMP-dependent PDE-II activity was found both in
homogenate-extract, and in several fractions eluted at the
region of NaCl gradient (303 3 mM NaC1, N = 4), located on
the initial ascending shoulder of peak #2 of PDE profile (Fig. 7).
This cGMP-stimulated PDE-II activity was limited to two or
four fractions in each eluate. The specific activity of PDE-II
recovered from these fractions was increased over that in the
homogenate-extract (Table 2). Activity of PDE-II is not in-
cluded into summary of major cAMP-PDE activities (Table 1);
however, comparison suggests that it is only a minor compo-
nent of total cAMP-PDE.
These results taken together suggest, at least indirectly, that
all five major types (families) of PDE isozymes [2, 3] are present
in LLC-PK1 cells. Quantitatively prominent are Ca2-CaM-
dependent PDE-I, which preferentially hydrolyzes cGMP
rather than cAMP under in vitro conditions, then the cAMP-
specific low-Km PDE-IV sensitive to rolipram, and finally
cGMP-specific (and Ca2-CaM-independent) PDE-V. On the
other hand, the cGMP-stimulated PDE-II and the PDE-III
isozymes are present in LLC-PK1 cells, but constitute only
minor components of the PDE isozyme system in LLC-PK1
cells.
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Fig. 4. The cGMP-PDE activities in Peak #1 of eluate from Mono-Q
column (fractions #75—95). A. In peak #1 (see also Fig. 3) cGMP-PDE
activities were assayed with Ca2 and CaM (--Es--), or in absence of
Ca2 (..A..A..). Ordinate: pmoles cGMP/mg protein/mm; abscissa:
"zones" of the peak are depicted as A, B, C; "zone D" is top fraction
of Ca2-CaM-dependent activity. B. Effects of PDE-V inhibitor (5
M zaprinast) and of PDE-I inhibitor (50 LM vinpocetine) on
cGMP-PDE in zones A, B, C and D as defined on the left panel. The
percent inhibition is shown as bars; each bar denotes mean SEM of
three experiments. * denotes values significantly different (P < 0.05, or
higher degree of significance, (-test).
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69 Kd
Fig. 5. Effect of inhibitors of PDE-!II (cilostamide and milrinone) and
PDE-IV (rolipram) upon PDE activities in peaks #2-5. Symbols are:
(•) inhibition by 3 JIM rolipram (RP); ( 3) JIM cilostamide; and (LI) by
3 jIM rnilrinone; they are expressed as % decrease in cAMP-PDE
activity. Each bar denotes mean 5EM of 4 experiments. * denotes
significant inhibition (P < 0.05, t-test); § denotes inhibition significantly
(P < 0.05, t-test) lower than inhibition by rolipram.
Cyclic-3',S'-nucleotide levels in intact LLC-PK1 cells
To discern functional roles for various PDE types in situ,
effects of several PDE isozyme-selective inhibitors upon AVP-
dependent cAMP accumulation were studied in intact LLC-PK1
cells. First, we established conditions of suitable time course
and dose-dependency conditions for stimulation by AVP (Fig.
8). Based on these data we tested the cAMP responses to AVP
early, after a two minute incubation (Fig. SB), and with an
established submaximal stimulatory dose (5 nM) of AVP (Fig.
8A). Under these conditions AVP elicited submaximal cAMP
accumulation in LLC-PK1 cells, which could be either en-
hanced or inhibited by changing cAMP/cGMP hydrolysis due to
pretreatment of LLC-PK1 cells with PDE isozyme specific
inhibitors.
First, we examined the effect of inhibitors of low-Km cAMP-
PDEs (that is, PDE-III and PDE-IV) rolipram, cilostamide and
milrinone (Fig. 9) upon cAMP levels. Treatment of cells with
rolipram alone (10 jiM) very slightly increased the basal cAMP
levels (not shown), but it elicited a marked enhancement of the
cAMP response to AVP (Fig. 9). In contrast, neither cilosta-
mide nor milrinone showed any effect on cAMP levels either
basal (not shown), or in the presence of stimulatory AVP dose
(Fig. 9).
Inhibitors of CaM, that is, W-7 and TFP, as well as vinpo-
cetine, an inhibitor of the catalytic unit of PDE-I [271, had no
effect on basal cAMP levels in LLC-PK1 cells. Unexpectedly,
W-7, vinpocetine and TFP all blunted the cAMP accumulation
in response to AVP in LLC-PK1 cells (Fig. 10). Extracellular
accumulation of cAMP in the medium was similarly decreased
by these drugs (data not shown).
Finally, to explore whether cGMP-stimulated PDE-Il activity
(Fig. 6) may influence cAMP levels in intact LLC-PK1 cells, the
cAMP response to AVP was determined in the presence of
H 1 2 3 4 5
Fig. 6. Fractions obtained from FPLC and subjected to electrophore-
sis. Amount of proteins were adjusted so that identical cAMP-PDE
activities (approximately 1.8 pmol/mg protein/mm) were applied for
lanes #2, 3,4, and 5: about 6 jig, 2 jig, 1 jig and 1 jig, respectively, were
applied to the lanes #2, 3, 4, and 5. Protein amounts applied to the lane
H (denotes homogenate extract) and the lane #1 (peak #1) were
approximately 6 jig. Arrow at right side denotes molecular wt marker
(kfla).
ANP, an established agonist of particulate guanylate cyclase in
LLC-PK1 cells [24, 25]. In these experiments, both cAMP and
cOMP levels were measured simultaneously in the same culture
well of LLC-PK1 cells. AVP elicited increase of cAMP but had
no effect on cGMP levels, conversely, incubation with ANP
increased cGMP, but not cAMP (Table 3). However, when
added together with AVP, addition of ANP resulted in small but
consistent attenuation ( — 13 + 3%; SEM mean, N = 4, P C
0.025, paired t-test) of the AVP-dependent cAMP accumulation
(Table 3).
Discussion
Synthetic pathways in LLC-PK1 cells for cAMP metabolism
via adenylate cyclase [22—24] and for cGMP metabolism via
guanylate cyclases [24, 25] in LLC-PK, cells, which are sensi-
tive to stimulation by well-established agonists, namely AVP,
ANP and EDRF, have been studied to considerable depth. In
contrast, very little is known about cyclic-3',5'-nucleotide
catabolism in LLC-PK1 cells via the system of PDE isozymes,
even though these enzymes are integral regulatory components
of cAMP and cGMP signalling as it is evident from studies of
non-renal tissues [1—5, 9—12]. The activities of PDE isozymes
determine the magnitude of the cellular response to a given
hormone [1—3, 6—8], can serve as point of mutual interaction, or
"cross talk", between different signalling pathways within the
cell [101, and may possibly play a role in cyclic nucleotide
compartmentalization [4, 9, 40, 41]. PDE isozymes may also be
a
X%
 
n
hi
bi
tio
n 
I 
I 
U'
 
K)
 
01
 
0 
0'
 
0 
-
o
 
0 K) -o 
w
,*
E 
' C) r 
_
_
_
_
_
_
 
*
 
co
) *
 
_
_
_
_
_
_
 
*
1—
I_
__
__
 
Rassier et a!: Metabolism of cAMP and cGMP in renal cells 95
Fractions containing
PDE-lI activity
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an important factor in coupling turnover of the second messen-
ger to specific cellular functions such as lipolysis [4, 8] or
glandular secretion [7].
In general, in LLC-PK1 cells the total and specific cGMP-
PDE activities are much higher than cAMP-PDE activities (Fig.
2, Table 1). This predominance of cGMP-PDE may contribute
to lower ambient content of cGMP compared to cAMP ob-
served in intact LLC-PK1 cells (Table 3).
Our present results indicate that homogenous clonal LLC-
PK1 renal epithelial cell line may contain five major types of
PDE isozymes [1, 3], albeit in different proportions. To our
knowledge, all five major types of PDEs were not found to be
present in one cell type. Three types of PDE isozymes are
abundant in LLC-PK1 cells, namely cAMP-specific PDE-IV,
cGMP-specific PDE-V and Ca2-CaM-dependent PDE-I which
hydrolyzes both nucleotides, but preferentially cGMP (Fig. 2,
Table 1). On the other hand, activities of PDE type-Ill and PDE
type-Il were detected as minor components of the PDE isozyme
pool in LLC-PK1 cells.
The presence of PDE-I activity in LLC-PK1 cells is well
documented, both in subcellular fractions (Fig. 2, Table 1) and
in Mono-Q column eluate (Figs. 3 and 4), both by the depen-
dence of Ca2-CaM and by its sensitivity to CaM inhibitors
TFP and W-7 as well as vinpocetine, an inhibitor of PDE-I
catalytic subunit [27] (Figs. 2 to 4). The PDE-I activity eluted in
the extract as a major (right side) portion of "peak #1",
overlaps with the cGMP-specific activity of PDE-V which
elutes in the initial (left side) portion of peak #1. Although these
two PDE activities did not elute as separate peaks from the
Mono-Q column, the presence of both PDE-I and PDE-V in
peak #1 is supported by the finding of differential sensitivity of
various subfractions (zones 1A to lD, Fig. 4) of peak #1 to
zaprinast, vinpocetine and TFP (Fig. 4). Thus, taken together,
the results strongly suggest that PDE-V activity elutes just
Basal +5 tM cGMP PDE-II
Homogenate extract 85 13C 105 19b 19.3 3.6
Eluate at 303 mi NaCI 52 3 98 46 7C
before PDE-I, in the front shoulder of "peak #1." This elution
pattern was observed also in studies of non-renal tissues [42].
Both cGMP-specific PDE-V and Ca2-CaM-dependent PDE-I
are most abundant in the cytosol of LLC-PK1 cells (Table 1,
Fig. 2).
The presence of high quantity of PDE-IV in LLC-PK1 cells is
indicated by high activity of Ca2-CaM-independent cAMP-
PDE which is sensitive to inhibition by 3 M rolipram in the
homogenate, in the cytosol and, to a lesser degree, also in the
membrane fraction (Table 1, Fig. 2). The ion exchange Mono-Q
chromatography resolved cAMP-PDE activity into four distinct
peaks (#2 through 5), and the presence of PDE-IV in these
peaks is affirmed by sensitivity to rolipram (Fig. 5), indepen-
dence of Ca2-CaM, substrate selectivity for cAMP, and also
by Western blot analysis using specific antibodies directed
against PDE-IV (Fig. 6). The chromatographic analysis sug-
gests the presence of several forms of rolipram-sensitive PDE-
IV, probably with different molecular charges (Fig. 3). Conceiv-
ably, PDE-IV activities in separate peaks #2 to #5(Figs. 3 and
5) might represent either products of different genes of the
PDE-IV subfamily, PDE-IVA to PDE-IVD [3, 35], and/or
PDE-IV isoforms resulting from alternative processing of these
genes [3, 35]. It is also possible that some chromatographic
fractions of PDE-IV (Figs. 4 and 5) might be proteolytic
products of one or more PDE-IV subtypes or isoforms. As a
rule, PDEs are polypeptides very sensitive to proteolysis [1, 2],
and the presence of more than one chromatographically distinct
proteolytic product of PDE-IV is not unprecedented [1]. At
least two fractions of rolipram-sensitive PDE-IV has been
resolved by HPLC chromatography in extracts for lymphocytes
[20, 42]. However, the origin and nature of chromatographic
fractions of PDE-IV found in LLC-PK1 cells (Figs. 4, 5, and 6)
ought to be clarified in future studies. The majority of PDE-IV
activity is found in cytosol (Table 1, Fig. 2).
Although the activity of cGMP-stimulated PDE-II is rather
low (Table 2), this PDE-II activity is detectable even in the
homogenate extract of LLC-PK1 cells, and is also identified in
higher specific activity as a minor but distinctly located (303
3 mM Nacl) cluster of fractions in the FPLC eluate (Fig. 7). On
the other hand, evidence that the PDE-III is present in LLC-
PK1 cells is not compelling, and lies solely on findings of
inhibitory effects to cilostamide and milrinone of cAMP-PDE in
peaks #2 to 5 (Fig. 5). By these criteria, the activity of PDE-III
in peaks #2 to 5 is rather low, especially when compared to
2000
1000
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0
0
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Table 2. Activity of cGMP-stimulated cAMP-PDE (PDE-II) in
homogenate extract and in eluate from Mono-Q column
0.25 . The PDE-II activity was assayed using 0.5 M [3H]-cAMP as a
' substrate without (basal) or with 5 /LM cGMP.
a Mean SEM (pmol cAMP/mg protein/mm); N = 3
b Significantly higher (P < 0.05, paired t-test) than basal
C Significantly higher (P < 0.05, t-test) than homogenate
0 1S11T I
75 100
Fraction
Fig. 7. Activity of cGMP-stimulated cAMP-PDE (PDE-II) in extracts
from LLC-PK1 cells. PDE-II elutes from the MONO-Q column in the
region (301 3 mri NaCI) on the ascending shoulder of peak #2, which
is part of whole elution profile portrayed on Figure 3. PDE-II values are
in Table 2.
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A Dose response
Time, minutes
Fig. S. The effect of AVP on cAMP content in LLC-PKJ cells. A.
cAMP accumulation in response to various doses of AVP after 2
minutes of incubation (representative experiment). The ED50 was 5 x
M AVP. B. Time course of cAMP accumulation in response to
incubation with 5 x 10 M AVP in LLC-PKI cells (representative
experiment). The 1/2 max cAMP increase was reached at 2 mm.
rolipram-sensitive PDE-IV. It is uncertain whether, based on
the present evidence, PDE-III activity found in the four frac-
tions (#2 to 5) along with PDE-IV may or may not reflect
different forms of PDE-III.
All the three main PDE types found in LLC-PK1 cells, that is,
PDE-I, PDE-IV and PDE-V, are located predominantly in
cytosol (Table 1, Fig. 2). The relative (%) responses to modu-
lators and inhibitors of PDEs found in the membrane fraction
are similar to those in the cytosol (Fig. 2). The homogenization
conditions were intentionally mild in order to avoid artifacts [5];
however, whether membrane-associated PDE activities are
endogenous membrane-bound PDE enzymes or remnants of
cytosolic PDEs persistently adsorbed on membranes after
homogenization and washing remains uncertain. Nevertheless,
the major PDEs in LLC-PK1 cells were mostly soluble while
analyzed by fractionation, but this does not exclude that in situ
Fig. 9. Effect of inhibitors (10 i each) of low Km cAMP-PDEs
(cilostamide (CS) and milrinone (MIL) for PDE-III and rolipram (RP)
for PDE-IV) upon accumulation of cAMP in response to 5 nM AVP.
Each bar represents mean SaM from eight experiments. All values
with AVP present, were significantly (P < 0.01, paired t-test) higher
compared to basal cAMP levels, * denotes value significantly (P < 0.01,
t-test) higher than values with AVP alone.
in intact LLC-PK1 cells, some apparently soluble PDEs are
discretely compartmentalized by elements of cytoskeleton or
via interactions with intracellular membranes.
PDE-isozyme, type-specific "second generation" inhibitors
U, 2, 27, 281 were used to discern which PDE isozymes present
in LLC-PK1 cells catabolize cAMP in response to AVP in intact
cells.
From all tested PDE-isozyme specific inhibitors, only rolip-
ram at relatively low concentration (10 M) markedly enhanced
the cAMP response to AVP, whereas cilostamide and milrinone
were without effect (Fig. 9). This finding is consistent with the
occurrence of abundant activity of PDE-IV in LLC-PK1 cells,
and suggests that one or more of the PDE type-IV isozymes [3,
351 plays a major role in AVP-dependent cAMP metabolism in
LLC-PK1 cells. On the other hand, the lack of effect of
cilostamide and milrinone upon basal or AVP-stimulated cAMP
suggest no apparent role of PDE-III, another PDE isozyme with
low Km and specificity for cAMP [1, 2, 43, 441, in cAMP
metabolism in LLC-PK1 cells.
Findings that the PDE-I inhibitor, vinpocetine [27], and
CaM-binding inhibitors, W-7 and TFP [27, 28], decreased rather
than increased the cAMP response to AVP (Fig. 10), deserves
a brief comment. All of these compounds decreased PDE-I in
cell-free preparation of LLC-PK1 cells (Fig. 4). W-7, TFP and
vinpocetine decreased cAMP content also in the medium (Re-
sults), which indicates that the drugs did not facilitate egress of
newly formed cAMP into the medium. The AVP-stimulated
adenylate cyclase in LLC-PK1 cells is CaM-dependent [23].
Therefore, inhibition of adenylate cyclase by added W-7 and
TFP may account for decreased AVP-dependent cAMP levels
(Fig. 10). However, vinpocetine inhibits the catalytic subunit at
PDE-I and does not bind on CaM [271. Vinpocetine blunted
AVP-stimulated cAMP accumulation in LLC-PK1 cells even in
the presence of 1.2 m IBMX (Table 4) when all PDEs are
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Table 3. Interactions of AVP and ANF on cAMP and cGMP in
LLC-PK1 cells
cAMP cGMP
Additions pmol/mg protein
—
None (basal) 3.5 0.3 1.1 0.1
5 x l0 M AVP 12.9 l.oa 1.1 0.1
i0 M ANF 3.4 0.1 1.9 o.la
5 X I0 sf AVP plus io- M ANF 11.6 13ab 1.9 o.la
Cells were incubated with hormones for 2 mm. Data are mean SEM
of 4 experiments.
a Values significantly higher (P < 0.05, paired t-test) than basal levelsb Significantly lower (P < 0.05, paired f-test) than value with AVP
alone
with 5 flM AVP
Fig. 10. Effects of inhibitors of Ca2-CaM-dependent PDE-I upon
AVP accumulat ion of cAMP in LLC-PK1 cells. Each bar represents
mean SEM of eight experiments. Values with 50 tM vinpocetine
(yIN), 100 M W-7 and 100 /SM TFP were significantly (P < 0.05, paired
f-test) lower than values with AVP without inhibitors.
blocked, or nearly so [19], suggesting that it also inhibits
adenylate cyclase. Apparently TFP, W-7 and vinpocetine,
while effective as blockers of PDE-I in cell-free preparations
[45], are not suitable tools to explore AVP-dependent cAMP
metabolism in intact LLC-PK1 cells.
Under present conditions AVP, at doses when it markedly
increased cAMP, had no effect on cGMP levels in LLC-PK
cells (Table 3). Concerning the role of PDE-II when cGMP was
increased in response to ANP, cAMP levels elevated in re-
sponse to AVP (Table 3) were significantly decreased. These
results are compatible with the interpretation that the blunting
of the cAMP response to AVP was due to increased activity of
PDE-II, which was stimulated by cGMP elevated in response to
ANP. Relatively small increase of cGMP elicited by ANP,
which causes cGMP accumulation primarily close to plasma
membrane of LLC-PK1 cells [411, was apparently sufficient to
stimulate PDE-II (Table 2). However, the physiological role of
this interaction in renal cells, observed in some other cell
systems [46], is unknown and remains to be further explored.
In conclusion, our study provides the first insights into
pathways of cAMP and cGMP metabolism in renal epithelial
LLC-PK1 cells, a model for study of the AVP-dependent cAMP
system [22.—26j. Results indicate that all five major types of PDE
isozymes [2, 3] can be present in LLC-PK1 cells, but the
predominant components are PDE-IV, PDE-I and PDE-V, all
located mainly in the cytosol. Observation showing that all five
major PDE types are present in homogenous cell population
appears to be without precedent. A recently reported study
comparing PDE isozyme composition in whole myocardial
tissue versus homogenous population of cardiomyocytes [42]
emphasizes the importance in determining the PDE isozyme
system in defined cells with specific functions [42]. Apparently
the key isozyme, PDE-IV, appears to be present in several (up
to four; Fig. 3), chromatographically distinguished forms. Fi-
nally, the studies on intact LLC-PK1 cells suggest a major role
for PDE-IV, perhaps minor role for PDE-II, but no discernable
Table 4. Effect of vinpocetine upon AVP-stimulated cAMP
accumulation in LLC-PK1 cells
pmol cAMP/mg protein
AVP + IBMX 192 22
AVP + IBMX + 10 M vinpocetine 117 4
AVP + IBMX + 50 sss vinpocetine 113 6
AVP + IBMX + 100 M vinpocetine ill 8
The cells were incubated in the presence of 1.2 mss IBMX and S nst
AVP without or with vinpocetine. Data are the mean SEM of 3
experiments.
a Significantly lower than value without vinpocetine (P < 0.01 paired
f-test)
role of PDE-III in AVP-dependent cAMP catabolism. The roles
of PDE-I and PDE-V in the control of cAMP and cGMP pools
related to actions of AVP and other agonists of adenylate and
guanylate cyclases remain to be clarified in future studies.
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